Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華潤醫療控股有限公司

China Resources Medical Holdings Company Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

The board of directors (the "**Board**") of China Resources Medical Holdings Company Limited (the "**Company**") is pleased to announce the unaudited consolidated results of the Company and its subsidiaries (the "**Group**") for the six months ended June 30, 2026 (the "**Reporting Period**") as follows:

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2026 – unaudited

		For the six months ended 30 June	
		2026	2025
	Note	***RMB'000***	*RMB'000*
REVENUE	*4*	**4,478,824**	4,524,803
Cost of sales		**(3,658,938)**	(3,812,276)
Gross profit		**819,886**	712,527
Other income	*5*	**47,678**	258,181
Other gains and losses, net	*6*	**(21,682)**	(1,062)
Administrative and other operating expenses		**(456,380)**	(470,261)
Impairment losses on financial and contract assets, net		**(20,290)**	(11,388)
Finance costs		**(16,561)**	(27,324)
Share of profits of associates		**41,487**	47,450

CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (CONT'D)
For the six months ended 30 June 2026 – unaudited

		For the six months ended 30 June	
		2026	2025
	Note	***RMB'000***	*RMB'000*
PROFIT BEFORE TAX	*7*	**394,138**	508,123
Income tax	*8*	**(74,750)**	(133,875)
PROFIT AND TOTAL COMPREHENSIVE INCOME FOR THE PERIOD		**319,388**	374,248
Attributable to:			
Equity shareholders of the Company		**264,902**	339,521
Non-controlling interests		**54,486**	34,727
		319,388	374,248
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY SHAREHOLDERS OF THE COMPANY	*10*		
Basic *(RMB yuan)*		**0.21**	0.27
Diluted *(RMB yuan)*		**0.21**	0.27

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

At 30 June 2026 – unaudited

	Note	30 June 2026 RMB'000	31 December 2025 RMB'000
NON-CURRENT ASSETS			
Property, plant and equipment		**4,703,734**	4,748,828
Right-of-use assets		**520,252**	553,368
Goodwill		**3,599,182**	3,599,182
Other intangible assets		**–**	6,484
Investments in associates		**1,028,812**	987,325
Receivables from invest-operate-transfer ("**IOT**") hospitals		**–**	6,745
Financial assets measured at fair value through profit or loss ("**FVTPL**")		**36,678**	38,972
Other financial assets at amortised cost		**102,506**	–
Deferred tax assets		**22,274**	12,283
Other non-current assets		**114,533**	108,686
Total non-current assets		**10,127,971**	10,061,873
CURRENT ASSETS			
Inventories		**239,995**	262,126
Trade and bills receivables	*11*	**1,156,343**	1,244,156
Contract assets		**–**	7,905
Prepayments, deposits and other receivables		**281,558**	263,434
Amounts due from related parties		**70,147**	44,364
Financial assets measured at FVTPL		**50,000**	–
Tax recoverable		**31,406**	–
Restricted and pledged bank deposits		**68,037**	90,998
Cash and cash equivalents		**959,724**	939,620
Total current assets		**2,857,210**	2,852,603
CURRENT LIABILITIES			
Trade and bills payables	*12*	**1,464,009**	1,662,199
Other payables and accruals		**1,501,742**	1,515,257
Amounts due to related parties		**487,396**	486,308
Interest-bearing bank borrowings		**701,695**	660,773
Lease liabilities		**40,786**	46,982
Tax payable		**37,573**	58,412
Total current liabilities		**4,233,201**	4,429,931

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (CONT'D)
At 30 June 2026 – unaudited

	Note	**30 June 2026** **RMB'000**	31 December 2025 *RMB'000*
NET CURRENT LIABILITIES		**(1,375,991)**	(1,577,328)
TOTAL ASSETS LESS CURRENT LIABILITIES		**8,751,980**	8,484,545
NON-CURRENT LIABILITIES			
Lease liabilities		**119,960**	145,341
Defined benefit plan obligations		**378,731**	373,940
Deferred income		**29,876**	32,966
Deferred tax liabilities		**28,286**	26,562
Amount due to a related party		**70,373**	–
Tax payable		**10,000**	–
Other liabilities		**16,686**	18,101
Total non-current liabilities		**653,912**	596,910
NET ASSETS		**8,098,068**	7,887,635
EQUITY			
Equity attributable to equity shareholders of the Company			
Share capital		**267**	267
Reserves		**6,711,054**	6,552,353
		6,711,321	6,552,620
Non-controlling interests		**1,386,747**	1,335,015
TOTAL EQUITY		**8,098,068**	7,887,635

NOTES

1. CORPORATE INFORMATION

China Resources Medical Holdings Company Limited (the "**Company**") is a limited liability company incorporated in the Cayman Islands.

During the period, the Company and its subsidiaries (collectively referred to as the "**Group**") were mainly engaged in (i) provision of general healthcare services; (ii) provision of hospital management services, sale of pharmaceuticals, medical devices and medical consumables and provision of other services in Chinese Mainland.

2.1 BASIS OF PREPARATION

The interim financial report of the Group for the six months ended 30 June 2026 has been prepared in accordance with International Accounting Standard ("**IAS**") 34 *Interim Financial Reporting,* issued by the International Accounting Standards Board ("**IASB**").

The interim financial report has been prepared in accordance with the same accounting policies adopted in the 2025 annual financial statements, except for the accounting policy changes that are expected to be reflected in the 2026 annual financial statements as detailed in note 2.2. The interim financial report does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2025. The auditor of the Company, KPMG, has expressed an unqualified opinion on these financial statements in their report dated 24 March 2026.

The interim financial report has been prepared under the historical cost convention, except for financial assets measured at FVTPL which have been measured at fair value. The financial information is presented in Renminbi ("**RMB**") and all values are rounded to the nearest thousand, except when otherwise indicated.

As at 30 June 2026, the Group's current liabilities exceeded its current assets by approximately RMB1,376 million. Considering the Group's expected operating cash flows and the Group's unutilised bank facilities as at 30 June 2026, the directors of the Company believe that the Group has sufficient financial resources to finance its operation and to meet its financial obligations as and when they fall due within the next twelve months from the end of the reporting period. Accordingly, the directors of the Company consider it is appropriate to prepare the interim financial report on a going concern basis.

2.2 CHANGES IN ACCOUNTING POLICIES

The IASB has issued a number of amendments to IFRS Accounting Standards that are first effective for the current accounting period. Of these, only the amendments to IFRS 9, *Financial instruments* and IFRS 7, *Financial instruments: Disclosures — Amendments to the classification and measurement of financial instruments*, are relevant to the Group's financial statements.

The amendments do not have a material impact on the Group's consolidated financial statements for the periods presented.

The Group has not applied any new or revised standard that is not yet effective for the current accounting period.

3. OPERATING SEGMENT INFORMATION

Management monitors the results of the Group's operating segments separately for the purpose of facilitating decision-making process of resource allocation and performance assessment. During the reporting period, the reportable segments of the Group are as follows:

(a) Hospital business: includes out-patient and emergency business, in-patient business corresponding to self-owned hospitals.

(b) Other business: includes operation management services, supply chain services and other services provided to participating hospitals and IOT/OT hospitals.

Segment performance is evaluated based on reportable segment results, which are measurements of adjusted profit/loss before tax. The adjusted profit/loss before tax is measured consistently with the Group's profit/loss before tax except that change in fair value of an equity investment measured at FVTPL, investment income on other financial assets at amortised cost, other unallocated income and gains, foreign exchange differences, net, other unallocated losses and expenses are excluded from such measurement.

Segment assets exclude goodwill, unallocated investments in associates, financial assets measured at FVTPL, other financial assets at amortised cost, cash and cash equivalents and pledged deposits and other unallocated head office and corporate assets as these assets are managed on a group basis.

Segment liabilities exclude interest-bearing bank borrowings and other unallocated head office and corporate liabilities as these liabilities are managed on a group basis.

Inter-segment sales and transfers are transacted with reference to the selling prices used for sales made to third parties at the then prevailing market prices.

The following is an analysis of the Group's revenue and results, and assets and liabilities by reportable operating segments.

Segment revenue and results

	Hospital Business *RMB'000*	Other Business *RMB'000*	Total *RMB'000*
Six months ended 30 June 2026			
Segment revenue	**4,316,930**	**161,894**	**4,478,824**
Inter-segment revenue	**–**	**–**	**–**
Consolidated revenue	**4,316,930**	**161,894**	**4,478,824**
Segment cost	**(3,517,187)**	**(141,751)**	**(3,658,938)**
Other income	**39,198**	**467**	**39,665**
Other gains and losses, net	**(14,816)**	**(3,751)**	**(18,567)**
Share of profits of associates	**–**	**41,487**	**41,487**
Administrative and other operating expenses	**(432,173)**	**(6,552)**	**(438,725)**
Finance costs	**(7,289)**	**(32)**	**(7,321)**
Impairment losses on financial and contract assets, net	**(22,398)**	**788**	**(21,610)**
Segment results	**362,265**	**52,550**	**414,815**
Investment income on other financial assets at amortised cost			**1,048**
Other unallocated income and gains			**6,965**
Change in fair value of an equity investment measured at FVTPL			**(2,294)**
Foreign exchange differences, net			**(769)**
Other unallocated losses and expenses			**(25,627)**
Profit before tax			**394,138**

	Hospital Business *RMB'000*	Other Business *RMB'000*	Total *RMB'000*
Six months ended 30 June 2025			
Segment revenue	4,258,616	266,187	4,524,803
Inter-segment revenue	–	–	–
Consolidated revenue	4,258,616	266,187	4,524,803
Segment cost	(3,588,771)	(223,505)	(3,812,276)
Other income	44,066	206,947	251,013
Other gains and losses, net	(5,660)	–	(5,660)
Share of profits of associates	–	47,450	47,450
Administrative and other operating expenses	(431,037)	(5,913)	(436,950)
Finance costs	(8,243)	–	(8,243)
Impairment losses on financial and contract assets, net	(14,263)	1,174	(13,089)
Segment results	254,708	292,340	547,048
Other unallocated income and gains			7,168
Change in fair value of an equity investment measured at FVTPL			5,330
Foreign exchange differences, net			(724)
Other unallocated losses and expenses			(50,699)
Profit before tax			508,123

Segment assets and liabilities

	Hospital business *RMB'000*	Other business *RMB'000*	Total *RMB'000*
As at 30 June 2026			
Segment assets	**8,995,840**	**1,333,018**	**10,328,858**
Unallocated assets			**6,806,680**
Elimination of inter-segment receivables			**(4,150,357)**
Total assets			**12,985,181**
Segment liabilities	**4,122,124**	**38,729**	**4,160,853**
Unallocated liabilities			**4,876,617**
Elimination of inter-segment payables			**(4,150,357)**
Total liabilities			**4,887,113**

	Hospital business *RMB'000*	Other business *RMB'000*	Total *RMB'000*
As at 31 December 2025			
Segment assets	8,898,660	1,317,610	10,216,270
Unallocated assets			6,853,480
Elimination of inter-segment receivables			(4,155,274)
Total assets			12,914,476
Segment liabilities	4,846,942	18,024	4,864,966
Unallocated liabilities			4,317,149
Elimination of inter-segment payables			(4,155,274)
Total liabilities			5,026,841

4. REVENUE

Disaggregated revenue information

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Types of goods or services		
In-patient	**2,530,042**	2,446,041
Out-patient and emergency	**1,786,888**	1,812,575
General healthcare services	**4,316,930**	4,258,616
Other services	**161,894**	266,187
Total	**4,478,824**	4,524,803
Timing of revenue recognition		
A point in time	**1,944,448**	2,051,482
Over time	**2,534,376**	2,473,321
Total	**4,478,824**	4,524,803

All of the Group's revenue is derived from the PRC.

5. OTHER INCOME

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Interest and investment income on:		
Financial assets measured at FVTPL	**247**	238
Other financial assets at amortised cost	**1,048**	–
Receivables from IOT hospitals	**414**	524
Bank deposits	**1,563**	4,443
Dividend income on an equity investment measured at FVTPL	**1,543**	2,880
Government grants	**9,803**	8,477
Write-off of payables	**2,610**	4,234
Enforcement payment from "Yan Hua Hospital"	**–**	206,423
Others	**30,450**	30,962
	47,678	258,181

6. OTHER GAINS AND LOSSES, NET

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Change in fair value of an equity investment measured at FVTPL	**(2,294)**	5,330
Foreign exchange differences, net	**(769)**	(724)
Loss on disposal of items of property, plant and equipment	**(5,772)**	(796)
Others	**(12,847)**	(4,872)
	(21,682)	(1,062)

7. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging:

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Cost of inventories sold	**1,723,602**	1,910,247
Depreciation of property, plant and equipment	**257,552**	259,467
Depreciation of right-of-use assets	**31,353**	28,693
Amortisation of intangible assets (included in cost of sales)	**540**	649
Total depreciation and amortisation	**289,445**	288,809
Impairment of trade receivables, net	**21,545**	12,689

8. INCOME TAX

The PRC enterprise income tax has been provided at the rate of 25% (six months ended 30 June 2025: 25%) on the estimated assessable income arising in the PRC during the period. No provision for Hong Kong profits tax has been made as the Group did not generate any assessable profits arising in Hong Kong during the period (six months ended 30 June 2025: Nil).

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Current — Chinese Mainland	**83,017**	113,236
Deferred	**(8,267)**	20,639
Total tax charge for the period	**74,750**	133,875

9. DIVIDEND

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Dividend recognised as distribution during the period:		
Final 2025 – RMB8.4 cents (2024: RMB8.2 cents)	**108,921**	106,327
Less: Dividend for shares held under the Share Award Scheme	**(2,720)**	(2,655)
	106,201	103,672

	For the six months ended 30 June	
	2026	2025
	RMB'000	*RMB'000*
Interim dividend declared after the interim period of RMB5.0 cents per ordinary share (2025: RMB5.0 cents)	**64,834**	64,834

The interim dividend has not been recognised as a liability at the end of the reporting period.

10. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY SHAREHOLDERS OF THE COMPANY

The calculation of the basic earnings per share amount is based on the profit attributable to ordinary equity shareholders of the Company of RMB264,902,000 (six months ended 30 June 2025: RMB339,521,000), and the weighted average number of ordinary shares of 1,264,292,000 (2025: 1,264,292,000) in issue during the interim period.

The Group had no potentially dilutive ordinary shares in issue during the interim period.

11. TRADE AND BILLS RECEIVABLES

	30 June 2026 *RMB'000*	31 December 2025 *RMB'000*
Trade receivables		
Public medical insurance program	**1,060,246**	1,152,710
Other customers	**362,443**	335,264
Bills receivable	**100**	1,265
	1,422,789	1,489,239
Impairment	**(266,446)**	(245,083)
	1,156,343	1,244,156

The Group's trading terms with its corporate customers are mainly on credit, except for new customers, where payment in advance is normally required. The credit periods range from 30 to 180 days. The Group seeks to maintain strict control over its outstanding receivables and has a credit control department to minimise credit risk. Overdue balances are reviewed regularly by senior management. The Group does not hold any collateral or other credit enhancements over its trade and bills receivable balances. Trade and bills receivables are non-interest-bearing.

An ageing analysis of the trade and bills receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	30 June 2026 *RMB'000*	31 December 2025 *RMB'000*
Within 1 year	**1,085,754**	1,187,103
1 to 2 years	**69,496**	53,179
Over 2 years	**1,093**	3,874
	1,156,343	1,244,156

12. TRADE AND BILLS PAYABLES

An ageing analysis of the trade and bills payables as at the end of the reporting period, based on the date of delivery of goods, is as follows:

	30 June 2026	31 December 2025
	RMB'000	*RMB'000*
Within 60 days	**652,759**	782,360
61 to 180 days	**541,058**	635,974
Over 180 days	**270,192**	243,865
	1,464,009	1,662,199

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

In the first half of the year 2026, the Group strived to adapt to changes in industry policies, actively responded to the reform of medical insurance payment, committed to boosting our core competitiveness in general healthcare services, and further explored and developed intelligent healthcare services and derivative health businesses.

In terms of general healthcare services, the Group continued to strengthen the medical core position of its hospitals in their respective regions. Huaibei Miner General Hospital* (淮北礦工總醫院) took the lead in establishing a compact urban medical group which has entered the phase of standardized operations. Focusing on discipline construction, the Group newly obtained approval for 1 provincial-level key specialty, 3 municipal-level key specialties and 1 national-level centralized certification. The Group also deepened collaborations with universities and high-level hospitals, for instance, Fushun Mining Bureau General Hospital of Liaoning Health Industry Group* (遼寧省健康產業集團撫礦總醫院) and Liaoning Province Health Industry Group Bengang General Hospital* (遼寧省健康產業集團本鋼總醫院) have been officially inaugurated as teaching hospitals affiliated with Shenyang Pharmaceutical University, and all four Grade III A hospitals in the Liaoning region have joined the Shengjing Healthcare Alliance. We have also deepened and refined cost management, with notable results in reducing proportion of drug and consumable costs in key regions including Pingkuang, Ruizhou and Xukuang. We have enhanced medical insurance refined management, with 11 directly-managed hospitals launched intelligent supervision systems, and the clinical pathway entry rate reached 84%, which effectively boosted the level of medical insurance management. We have expanded cooperations across the healthcare ecosystem, Guangdong 999 Brain Hospital* (廣東三九腦科醫院) participated in organoid projects by China Resources Life and Health Research Institute, and progress have been made in different aspects including tissue collection, organoid cultivation, biobank construction, technology development and translational applications. In the aspect of Good Clinical Practice (GCP) for medications, 2 new departmental GCP professional qualifications and 41 GCP projects have been added. We have also promoted digital and intelligent development, broadened the application of AI in medical record quality control, medical insurance management and medical check-up services. The datasets for brain-specific diseases was recognized as a high-quality dataset achievement of central state-owned enterprises by the SASAC, and was presented at the 2026 World Artificial Intelligence Conference.

In terms of intelligent healthcare services and derivative health businesses, the Group has combined the resources and positioning of each hospital, and has classified the construction standards for health management centers into a three-tier system: flagship, primary and fundamental, and the Group defined 4 core functions for the health management centers under the hospitals, being customer management, medical check-up services, healthcare management and cross-regional business undertaking. The overall revenue from healthcare management in the first half of the year 2026 showed steady growth. Among which, the Wugang region optimized appointment scheduling with several new customers onboard. In the Fuxin region, medical check-up services were newly added at the Fuxin Mining Staff Headquarters. Progress has been made in the derivative health businesses, in which an online health mall has been officially launched and the offline Beijing Runxin Lianyi Pharmaceutical Co., Ltd. Shenzhen Chunsun Pharmacy* (北京潤心聯醫醫藥有限公司深圳春筍大藥房) commenced operation.

Scale of our operation

As of June 30, 2026, the Group managed and operated a total of 90 medical institutions in 10 provinces and cities in the PRC. During the Reporting Period, the number of out-patient and emergency visits and in-patient visits of our self-owned hospitals were approximately 5.37 million and 0.27 million, respectively, representing the respective period-over-period increase of 5.2% and 0.3%.

List of Medical Institutions under the Group's Management and Operation

Province/City	Grade III Hospitals	Grade II Hospitals	Grade I Hospitals	Community and Medical Clinic	Total
Beijing	2	1	4	6	13
Liaoning	5	10	7	7	29
Jiangxi	1	3	2	1	7
Shandong	–	1	–	3	4
Shanxi	–	1	–	–	1
Jiangsu	–	1	–	–	1
Anhui	1	1	11	7	20
Hubei	2	–	–	7	9
Guangdong	1	1	–	2	4
Guangxi	–	1	1	–	2
Total	12	20	25	33	90

Notes:

(1) The hospital grading system in Chinese Mainland is a review system implemented by the health administrative departments of the PRC for medical institutions within their administrative jurisdiction, including the criteria for reviewing hospital qualifications. Currently, China operates a three-tier healthcare service system; Grade III hospitals, as high-quality medical resources, represent the highest level of medical qualifications in Chinese Mainland.

(2) Considering the services provided by the Group to the Mentougou Traditional Chinese Medicine Hospital and Mentougou Healthcare Hospital for Women and Children were terminated with effect from July 1, 2026, the medical institutions during the period does not include the above two hospitals. For further details, please refer to the announcement of the Company dated June 26, 2026.

Operating data for 2026H1

Type	Number of beds in operation	Utilization rate of beds	Number of patients: Out-patient and emergency	Number of patients: In-patient	Revenue from medical business (RMB'000): Revenue from out-patient and emergency visits	Revenue from in-patient visits	Revenue from physical examination	Total
Self-owned Hospitals	**17,606**	**85.0%**	**5,369,171**	**271,896**	**1,700,733**	**2,530,042**	**86,155**	**4,316,930**

Operating data for 2025H1

Type	Number of beds in operation	Utilization rate of beds	Number of patients: Out-patient and emergency	Number of patients: In-patient	Revenue from medical business (RMB'000): Revenue from out-patient and emergency visits	Revenue from in-patient visits	Revenue from physical examination	Total
Self-owned Hospitals	18,286	80.6%	5,103,793	270,957	1,721,993	2,446,041	90,582	4,258,616

Note:

1. In respect of the operating data statistics, the abovementioned self-owned hospitals refer to all consolidated hospitals.

Financial data

The table below sets out the key financial figures of the Group by business segments for the specific periods:

	2026H1	2025H1	Period-over-Period Change	
	RMB'000	*RMB'000*	*RMB'000*	*Percentage*
Hospital Business				
Revenue	**4,316,930**	4,258,616	58,314	1.4%
— Revenue from out-patient and emergency visits	**1,786,888**	1,812,575	-25,687	-1.4%
— Revenue from in-patient visits	**2,530,042**	2,446,041	84,001	3.4%
Segment gross profit	**799,743**	669,845	129,898	19.4%
Segment results	**362,265**	254,708	107,557	42.2%
Other Business				
Revenue	**161,894**	266,187	-104,293	-39.2%
Segment gross profit	**20,143**	42,682	-22,539	-52.8%
Segment results	**52,550**	292,340	-239,790	-82.0%
Total				
Revenue	**4,478,824**	4,524,803	-45,979	-1.0%
Segment gross profit	**819,886**	712,527	107,359	15.1%
Segment results	**414,815**	547,048	-132,233	-24.2%

Notes:

During the Reporting Period:

(1) Hospital business includes: out-patient and emergency business and in-patient business corresponding to self-owned hospitals.

(2) Other business include: operation management services, supply chain services and other services provided to participating hospitals and IOT (the "invest-operate-transfer" model)/OT (the "operate-transfer" model) hospitals. As at June 30, 2026, IOT hospitals include Mentougou Traditional Chinese Medicine Hospital and Mentougou Healthcare Hospital for Women and Children. The services provided by the Group to the Mentougou Traditional Chinese Medicine Hospital and Mentougou Healthcare Hospital for Women and Children were terminated with effect from July 1, 2026. For further details, please refer to the announcement of the Company dated June 26, 2026.

Hospital Business

During the Reporting Period, the revenue of the hospital business segment was RMB4,317 million, representing a period-over-period increase of 1.4%. Among which, out-patient and emergency visits increased by 5.2% and in-patient visits increased by 0.3%, each of the revenue per out-patient and emergency visit decreased by 6.1% and the revenue per in-patient visit increased by 3.1%.

During the Reporting Period, we made efforts to reduce the impact of the decline in revenue per visit on the hospital business's profit through improving quality and efficiency. The gross profit of the hospital business segment was RMB800 million, representing a period-over-period increase of 19.4%, with a gross profit margin of 18.5% (Corresponding Period: 15.7%); the profit of the hospital business segment recorded RMB362 million, representing a period-over-period increase of 42.2%.

Other Business

During the Reporting Period, the revenue of other business was RMB162 million, representing a period-over-period decrease of 39.2%, and the segment profit of other business was RMB53 million, representing a period-over-period decrease of 82.0%. After excluding the one-off compensation for the management fees and the supply chain loss under the Yan Hua IOT Agreement of approximately RMB210 million received by the Group in 2025 ("**Yan Hua Compensation**"), the segment profit representing a period-over-period decrease of 38.8%. During the Reporting Period, the IOT business of the Company has been scaled back, the corresponding profit contribution of which has decreased during the Reporting Period.

Administrative and other operating expenses

During the Reporting Period, the Group's administrative and other operating expenses totaled RMB456 million, decreased by 3.0% period-over-period, due to the effectiveness of expense control measures.

Finance costs

During the Reporting Period, the finance cost of the Group amounted to approximately RMB16.56 million (Corresponding Period: approximately RMB27.32 million). The decrease in the finance costs was in line with the Group's proactive adjustment of debt structure, reduce the weighted average financing cost and total borrowings through measures such as loan replacement and repayment of loans.

Income tax

During the Reporting Period, the Group's income tax amounted to approximately RMB75 million (Corresponding Period: approximately RMB134 million), decreased by 44.2% period-over-period. The decrease in income tax is mainly due to the one-off Yan Hua Compensation received in 2025, which had enlarged the domestic taxable income base in the Corresponding Period.

Net profit

As a result of the foregoing, the Group recorded a net profit of RMB319 million for the Reporting Period, representing a period-over-period decrease of 14.7%. After excluding the one-off Yan Hua Compensation in 2025 and the corresponding enterprise income tax, the net profit would increase by 45.6% as compared to the Corresponding Period. Such increase in net profit was mainly attributable to increase in profit contributed by the member hospitals under the Group, which is benefitted from the hospital's initiatives such as reaching patients through multiple channels to unlock latent medical demand, increasing the number of out-patient and emergency visits, and actively exploring cross-hospital resource integration and complementary cooperation models to strengthen synergy to increase the number of in-patient visits. Concurrently, while growing the revenue, the hospitals also enhance refined management, reduce the proportion of drug and consumable costs, and controlled operating expenses, thereby lifted the hospitals' profit contribution.

Liquidity and Financing

We adopt a prudent treasury management policy to maintain a solid and healthy financial position. The Group funds its operations principally from cash generated from its operations and bank facilities. Its cash needs relate primarily to operating activities, business expansion, repayment of liabilities as they become due, capital expenditures, and interest and dividend payments.

As at June 30, 2026, the Group's consolidated bank balances and cash, certificate of deposits and bank financial products amounted to approximately RMB1.180 billion in total (December 31, 2025: approximately RMB1.031 billion) which were primarily denominated in RMB.

As at June 30, 2026, the Group had obtained offshore revolving term loan facility of HK$3.40 billion (or its equivalent in U.S. dollar or RMB), among them, HK$2.60 billion is of a term of one year which shall be automatically renewed if the relevant bank does not notify otherwise. In addition, the Group had also obtained from banks onshore facilities of RMB4.45 billion as of the date of this announcement. As at June 30, 2026, the Group had bank borrowings of RMB702 million, which consists entirely of interest-bearing bank loans (as at December 31, 2025, the Group had bank borrowings of RMB661 million, which consists entirely of interest-bearing bank loans), all the bank borrowings consists entirely of fixed interest rates, and unutilized bank facilities of amounted to approximately HK$2.94 billion and RMB4.12 billion (equivalent to approximately RMB6.68 billion in total).

Gearing Ratio

As at June 30, 2026, on the basis of interest-bearing borrowings divided by total assets, the Group's gearing ratio was 5.9% (December 31, 2025: 5.1%). In addition, the carrying value of each of our wealth management products as at June 30, 2026 did not exceed 5% of the Group's total asset value.

Exposure to Fluctuation in Exchange Rates, the Interest Rate Risk and Other Risks

As of June 30, 2026, the Group does not undertake operating transactions in foreign currencies and all of the Group's bank borrowings are denominated in RMB.

The Group has not used any financial instruments to hedge against its exposure to currency risk. The management manages the currency risk by closely monitoring the movement of the foreign currency rates and considers hedging against significant foreign exchange risk exposure should such need arise.

We are also exposed to risk of talent shortage, and therefore we have been taking an active approach to attract, train and retain sufficient qualified doctors, management personnel and other medical staff members, in the absence of which the business of hospitals affiliated to the Group would be affected to a certain extent. Please refer to the paragraph headed "Management Discussion and Analysis — Employees and Remuneration Policy" for the relevant measures undertaken.

We also recognise that our relationship with patients and partners is key to the resilient development of the Group. We strive to provide quality services and medical staffs with extensive experiences to our patients. By leveraging on sophisticated medical skills and equipment, we try our best to cater to our patients' needs for medical treatments. We also cooperate with our partners to achieve the sustainable development of our business.

Contingent Liabilities

As at June 30, 2026, the Group did not have any contingent liabilities or guarantees that would have a material impact on the financial position or operations of the Group.

Pledge of Assets

As of June 30, 2026, the Group did not have any material pledge of assets.

Employees and Remuneration Policy

As of June 30, 2026, the Group had a total of 19,182 full-time employees (December 31, 2025: 19,687 employees). For the Reporting Period, the staff costs (including Directors' remuneration in the form of salaries and other benefits) was approximately RMB1,725 million (Corresponding Period: RMB1,716 million).

The Group ensured that the remuneration packages of employees remain competitive and the remuneration level of its employees was determined on the basis of performance with reference to the profitability of the Group, industry remuneration standards and market conditions within the general framework of the Group's remuneration system.

For talent acquisition and continuous development, the Group offers training programs as well as leadership and talent development programs for talents with different academic backgrounds. The Group believes that direct and effective communication is essential for good partnership built-up between management and employees. The Group holds regular meetings and forums to brief employees on Company developments and obtain their feedbacks and suggestions.

In respect of our staff, the Group strictly complies with the relevant laws and regulations, and has formulated the internal policy regarding the diversity in the workforce (including senior management). The Group respects and values the diversity of individual employees, including but not limited to gender, age, race, religious belief, cultural background, education level, work experience, skills and specialties etc., adheres to the principle of fair and open employment, firmly opposes discrimination, prejudice, harassment and unfair treatment, ensures all employees are treated in accordance with appropriate procedures in terms of recruitment, training, performance appraisal, compensation and benefits, and promotion, and creates a fair, just and transparent working environment.

Contractual Obligations

As at June 30, 2026, the Group did not have any significant contractual obligations arisen outside of the ordinary and usual course of business of the Group and of a capital nature that would have a material effect on the financial position or operations of the Group.

Interim Dividend

The Board has resolved to declare an interim dividend of RMB5 cents per Share (equivalent to HK$5.78 cents per Share at the exchange rate of RMB1:HK$1.15587, being the average benchmark exchange rate of RMB to HK$ as published by the People's Bank of China during the five business days ending on Tuesday, August 25, 2026 (inclusive)) for the six months ended June 30, 2026 (the "**2026 Interim Dividend**") (Corresponding Period: RMB5 cents per Share). The 2026 Interim Dividend will be distributed on Monday, October 26, 2026 to Shareholders whose names appear on the register of members of the Company on Friday, September 18, 2026, being the record date for determining Shareholders' entitlement to the 2026 Interim Dividend.

The 2026 Interim Dividend will be payable in cash to each Shareholder in HK$, unless an election is made to receive the same in RMB. Shareholders will be given the option to elect to receive all (but not part, save in the case of HKSCC Nominees Limited, which may elect to receive part of its entitlement in RMB) of the 2026 Interim Dividend in RMB. To make such election, Shareholders should complete the dividend currency election form, which is expected to be despatched to Shareholders on or around Wednesday, September 23, 2026, and return it to the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong not later than 4:30 p.m. on Friday, October 9, 2026. Shareholders who are minded to elect to receive all of the 2026 Interim Dividend in RMB by cheques should note that (i) they should ensure that they have an appropriate bank account to which the RMB cheques for dividend can be presented for payment; and (ii) there is no assurance that RMB cheques can be cleared without material handling charges or delay in Hong Kong or that RMB cheques will be honoured for payment upon presentation outside Hong Kong. The cheques are expected to be posted to the relevant Shareholders by ordinary post on Monday, October 26, 2026 at the Shareholders' own risk.

For the avoidance of doubt, if no election is made by a Shareholder or no duly completed dividend currency election form in respect of that Shareholder is received by the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, by 4:30 p.m. on Friday, October 9, 2026, such Shareholder will automatically receive the 2026 Interim Dividend in HK$.

All payments of the 2026 Interim Dividend in HK$ will be made in the usual way on Monday, October 26, 2026. If Shareholders wish to receive the 2026 Interim Dividend in HK$ in the usual way, no action is required. Shareholders should seek professional advice from their own tax advisors regarding the possible tax implications of such dividend payment.

Closure of Register of Members

For determining the entitlement to the 2026 Interim Dividend, the register of members of the Company will be closed from Tuesday, September 15, 2026 to Friday, September 18, 2026, both days inclusive, during which period no transfer of shares will be registered. In order to qualify for the entitlement to the 2026 Interim Dividend, all transfers of shares accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712–1716, 17/F, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong for registration not later than 4:30 p.m. (Hong Kong time) on Monday, September 14, 2026.

Events After the Reporting Period

On June 26, 2026, the relevant contracting parties of the Hospital IOT Agreements entered into a supplemental agreement upon amicable negotiations, pursuant to which the Hospital IOT Agreements were terminated with effect from July 1, 2026, and the remaining balance of the Cooperation & Development Funds and management fees payable to the Group, after deducting other amounts, in the aggregate amount of approximately RMB4.36 million was repaid by July 30, 2026. For further details, please refer to the announcement of the Company dated June 26, 2026.

Save as disclosed above, the Group had no other significant subsequent events since the end of the Reporting Period and up to the date of this announcement.

Significant Investments, Acquisitions and Disposals, and Investments in Joint Venture(s) and Associate(s)

As at June 30, 2026, save as disclosed in the sections headed "Investments in Associates — JR Renkang & JR Holdings" of this announcement, the Group did not have any significant investments held, and material acquisitions and disposals of subsidiaries, associates or joint ventures during the Reporting Period.

Investments in Associates — JR Renkang & JR Holdings

On June 28, 2020, the Group entered into a restructuring agreement on the establishment of two associates with Jing Mei Group, pursuant to which Beijing Jing Run Renkang Hospital Management Co., Ltd. ("**JR Renkang**") and Beijing Jing Run Renkang Holdings Co., Ltd. ("**JR Holdings**") were established and held by the Group and Jing Mei Group as to 49% and 51%, respectively. Upon establishment, JR Renkang and JR Holdings became associates of the Group. Please refer to the announcement of the Company dated June 28, 2020 for further details.

As at June 30, 2026, JR Holdings and JR Renkang were associates of the Group. Pursuant to the relevant arrangements under the abovementioned agreement, JR Holdings has been the sponsor of Jing Mei Hospital Group and JR Renkang has been providing hospital management services to the Jing Mei Hospital Group. The Group's investment costs in JR Holdings and JR Renkang amounted to RMB874 million and RMB2.45 million, respectively. As at June 30, 2026, the Group holds a 49% equity interest in each of JR Holdings and JR Renkang, with a carrying amount of investment of RMB962 million and RMB62 million, respectively, representing approximately 7.9% of the total assets of the Group in total.

During the Reporting Period, JR Holdings and JR Renkang achieved a revenue of RMB127 million in aggregate, resulting in a combined net profit of RMB86 million. The net profit of JR Holdings and JR Renkang attributing to the Group was RMB42 million. During the Reporting Period, the Group did not receive dividend from JR Holdings and JR Renkang.

During the Reporting Period, the Jing Mei Hospital Group was the leading hospitals in Mentougou district and one of the core medical institutions in the western region of Beijing. The Group believes that the investment in JR Holdings and JR Renkang, as well as the cooperation with the Jing Mei Group, fully leverages the respective strengths of the Jing Mei Group and the Group. The Group will regularly review its investment strategy to adapt to changes in market conditions.

Future Plans for Material Investment or Capital Assets

As at the date of this announcement, there are no concrete plans to acquire any material investment or capital assets other than those conducted in the Group's ordinary course of business.

FUTURE OUTLOOK

In July 2026, the State Council has issued the "15th Five-Year Plan for National Health", promoting a shift towards the "focus on health" approach. The Group's "15th Five-Year" Strategy is highly aligned with the national strategic priorities. We will accelerate the transformation and upgrading of our traditional integrated healthcare services, foster the development of intelligent healthcare services businesses, and strategically expand into derivative health businesses.

The Group will fully implement strategic leadership. We will promote and refine the strategic planning of the "15th Five-Year Plan" in the headquarters and regional entities, comprehensively review and clarify the development and positioning of each medical institution, and improve their operation through differentiated and tiered management strategies. The Group will accelerate our business transformation and upgrading. Firstly, we will strengthen our general healthcare services, persist in integrating with regional healthcare planning and drive the urban medical group led by Huaibei Miner General Hospital* (淮北礦工總醫院) to achieve tangible results, discipline construction and projects planning will be refined, as well as the disciplinary evaluation system. We will also strengthen collaborations with high-level hospitals and universities and support core medical institutions to serve as clinical peaks and leverage their radiating and driving roles, and promote refined medical insurance management and achieve full coverage of intelligent management systems. Secondly, we will steadily promote intelligent healthcare services, and establish a full-cycle intelligent healthcare service ecosystem, expanding service delivery to hospitals, enterprises, and households, and accelerating internal capability building and market expansion. Thirdly, the Group will explore and develop derivative health businesses, focus on deepening engagement with the entire customer domain, broadening the type of health products across all categories, and diversifying the product sources across all channels to effectively meet hospitals' product needs and establishing market-oriented operational capabilities. We will establish a management system for medical supplies, logistics and infrastructures, and further strengthen the output of professional management capabilities.

COMPLIANCE WITH THE CG CODE

The Company recognises the importance of incorporating elements of good corporate governance into the management structures and internal control procedures of the Group so as to achieve effective accountability and safeguard the interests of the Shareholders.

The Company confirms that it has complied with all applicable code provisions of the CG Code contained in Part 2 of Appendix C1 to the Listing Rules during the Reporting Period.

The Board will review its corporate governance structure and practices from time to time and shall make necessary arrangements when the Board considers appropriate.

MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code (on terms no less exacting than the required standard set out in the Model Code) as its own code of conduct for dealings in securities of the Company by the Directors. Having made specific enquiry with all Directors, the Company confirmed that all Directors complied with the Model Code throughout the Reporting Period. Senior management, executives and staff who, because of their offices in the Company, are likely to possess inside information of the Company have also been requested to comply with the provisions of the Model Code and the Company confirmed that there was no incident of non-compliance of the Model Code by such employees throughout the Reporting Period.

OTHER INFORMATION

Yan Hua IOT Agreement Dispute

In respect of the litigation case between the Company and the Yanhua Parties (i.e. the Yan Hua Phoenix and Yan Hua Hospital) regarding the performance of the Yan Hua IOT Agreement in 2019, the Beijing Higher People's Court handed down the final judgment (2020 Jing Minzhong No.110) on November 22, 2021, which rejected the appeal filed by the Yanhua Parties in 2020 and upheld the original judgment in 2019 as follows: the major details are as follows: (1) the unilateral termination of Yan Hua IOT Agreement by Yan Hua Phoenix and Yan Hua Hospital is declared to be void and that the parties shall continue to perform its obligations under the Yan Hua IOT Agreement; (2) the amount of RMB14,400,000, being the damages for breach of the Yan Hua IOT Agreement, is to be paid by Yan Hua Phoenix to CR Hospital Management & Consulting; (3) other reliefs sought by CR Hospital Management & Consulting shall be dismissed; and (4) other counterclaims of Yan Hua Phoenix and Yan Hua Hospital shall be dismissed. As the Yanhua Parties have been negligent in complying with the abovementioned final judgment, the Company then filed an application for enforcement with the Beijing Second Intermediate People's Court in January 2022, and then accordingly received the liquidated damages amounted to RMB14,400,000 and related overdue fine paid by Yan Hua Phoenix through the court enforcement procedure in April 2022. However, due to the Yanhua Parties' persistent refusal to perform the Yan Hua IOT Agreement, the Company brought a separate lawsuit against the Yanhua Parties in September 2022 to seek compensation for the losses suffered by the Company as a result of the Yanhua Parties' breach of the Yanhua IOT Agreement (including the management fee and supply chain fee receivable by the Company from 2019 to the filing date).

The Beijing Second Intermediate People's Court handed down the original judgment on December 22, 2023 (the "**Original Judgment**"), adjudicating as follows: (1) ordering that Yan Hua Hospital should pay RMB3,057,500 for the annual repayment of investment and, in addition, related overdue fine; (2) ordering that the Yanhua Parties should pay RMB41,237,300 for the loss of hospital management fee and, in addition, related overdue fine; and (3) ordering that the Yanhua Parties should pay RMB146,666,700 for the loss from the cessation of comprehensive service transaction and, in addition, loss of interest. Both parties appealed against the Original Judgment. Subsequently, on December 27, 2024, the Beijing High People's Court has ruled to agree with the withdrawal of the appeal by the Yanhua Parties, and handed down the final judgment upholding the Original Judgment. On February 20, 2025, the Company received the enforcement payment of RMB209,480,000 transferred by the Court.

The Company has submitted a case filing application in relation to the Yan Hua IOT Agreement dispute to the Beijing Second Intermediate People's Court in June 2025, seeking the Court's ruling for termination of the Yan Hua IOT Agreement, and ordering Yan Hua Phoenix and/or Yan Hua Hospital to pay the relevant compensation for breach of contract and to return the relevant funds under the Yan Hua IOT Agreement (the "**New Litigation**"). The Company has received service documents issued by the Beijing Second Intermediate People's Court, confirming that the court has formally accepted the filing of the New Litigation on June 24, 2025.

Please refer to the announcements published by the Company on January 15, 2019, January 21, 2019, April 17, 2019, November 23, 2021, February 21, 2025 and July 7, 2025 for more details.

The Company will issue further announcements in a timely manner in accordance with the requirements of the Listing Rules and the SFO, as and when required.

REVIEW OF INTERIM RESULTS

The Audit Committee has reviewed the unaudited consolidated interim results of the Group for the Reporting Period and considered that they were prepared in compliance with the relevant accounting standards, the Listing Rules and the applicable legal requirements, and that the Company has made appropriate disclosure thereof.

The interim financial report for the six months ended June 30, 2026 is unaudited, but has been reviewed by KPMG, in accordance with Hong Kong Standard on Review Engagements 2410 "Review of interim financial information performed by the independent auditor of the entity", issued by the Hong Kong Institute of Certified Public Accountants, whose unmodified review report will be included in the interim report to be published.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

During the Reporting Period, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities (including sale or transfer of treasury shares as defined under the Listing Rules). The Company did not have any treasury shares (as defined under the Listing Rules) as at June 30, 2026.

PUBLICATION OF THE UNAUDITED INTERIM RESULTS AND INTERIM REPORT

This interim results announcement is published on the websites of the Stock Exchange at www.hkexnews.hk and of the Company at www.crmedical.hk, respectively. The interim report of the Company for the Reporting Period will be published on the Stock Exchange's and the Company's websites, respectively, in due course.

DEFINITIONS

"Audit Committee"	the audit committee of the Board
"Board" or "Board of Directors"	the board of Directors of our Company
"CG Code"	Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"China" or "PRC"	the People's Republic of China excluding, for the purpose of this announcement, Taiwan, the Macau Special Administrative Region and Hong Kong
"Company" or "our Company"	China Resources Medical Holdings Company Limited (華潤醫療控股有限公司), a company incorporated in the Cayman Islands with limited liability on February 28, 2013
"Cooperation & Development Funds"	the cooperation and development funds in the total amount of RMB40 million in which the Group invested in the Mentougou Traditional Chinese Medicine Hospital and the Mentougou Healthcare Hospital for Women and Children respectively pursuant to the Hospital IOT Agreements for operational and development purposes

"Corresponding Period" or "2025H1"	the period from January 1, 2025 to June 30, 2025
"CR Hospital Management & Consulting"	China Resources Hospital Management & Consulting Co. Ltd. (華潤醫院管理諮詢有限公司) (formerly known as Beijing Phoenix United Hospital Management Consulting Co. Ltd. (北京鳳凰聯合醫院管理諮詢有限公司), Beijing Phoenix United Hospital Management Co., Ltd. (北京鳳凰聯合醫院管理有限公司) and Beijing Phoenix United Hospital Management Joint Stock Co., Ltd. (北京鳳凰聯合醫院管理股份有限公司)), a limited liability company established under the laws of the PRC on November 6, 2007, and a wholly-owned subsidiary of our Company
"Director(s)"	the director(s) of the Company
"Group", "we" or "us"	our Company and its subsidiaries
"HK$" and "cent(s)"	Hong Kong dollar and cent(s), respectively, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"Hospital IOT Agreements"	the series of agreements entered into between the Group and the Mentougou District People's Government of Beijing Municipality (the rights and obligations of which under the agreements were subsequently assumed by the Mentougou District Health Commission of Beijing Municipality since June 2019) (the "**Mentougou District Government**") between the respective periods from June 6, 2012 to 2023, and from September 23, 2014 to 2023 (as amended) with respect to the invest-operate-transfer of Mentougou Traditional Chinese Medicine Hospital and the Mentougou Healthcare Hospital for Women and Children
"IOT"	the "invest-operate-transfer" model

"IOT Hospitals"	third-party hospitals and clinics, which we manage and operate under the IOT model
"Jing Mei Group"	Beijing Jing Mei Group Company Limited* (北京京煤集團有限責任公司), a company established in the PRC with limited liability. Jing Mei Group is a wholly-owned subsidiary of Beijing Energy Holding Company Limited* (北京能源集團有限責任公司), which currently holds the entire interest in and the sponsorship of Jing Mei Hospital and its affiliated medical institutes
"Jing Mei Hospital"	Jing Mei Hospital* (北京京煤集團總醫院)
"Jing Mei Hospital Group"	collectively, Jing Mei Hospital and its affiliated grade I hospitals and community clinics
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"Mentougou Healthcare Hospital for Women and Children"	the Mentougou Healthcare Hospital for Women and Children of Beijing Municipality, a not-for-profit hospital established under the laws of the PRC in 1983 and wholly owned by the Mentougou District Government
"Mentougou Traditional Chinese Medicine Hospital"	the Mentougou Traditional Chinese Medicine Hospital of Beijing Municipality, a not-for-profit hospital established under the laws of the PRC in 1956 and wholly owned by the Mentougou District Government
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix C3 to the Listing Rules
"OT"	the "operate-transfer" model
"OT Hospital(s)"	third-party hospital(s) which the Group manages and operates under the OT model
"Reporting Period" or "2026H1"	the period from January 1, 2026 to June 30, 2026

"RMB"	Renminbi, the lawful currency of the PRC
"SFO"	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
"Share(s)"	share(s) with par value of HK$0.00025 each in the capital of our Company
"Share Award Scheme"	the share award scheme of the Company adopted by the Board pursuant to a resolution passed by the Board on July 7, 2014, as amended by the Board on May 25, 2015 and August 31, 2018. Such share award scheme expired on July 6, 2024
"Shareholder(s)"	holder(s) of the Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"U.S. dollar"	United States dollar, the lawful currency of the United States of America
"Yan Hua Hospital"	Yan Hua Hospital* (北京燕化醫院)
"Yan Hua Hospital Group"	collectively, Yan Hua Hospital and the community clinics affiliated with Yan Hua Hospital
"Yan Hua Hospital Investment Management Agreement"	the hospital investment management agreement dated February 4, 2008, which was supplemented in April 2008, December 2010, June 2011, July 2013, September 2013 and October 2013, and were entered into between CR Hospital Management & Consulting, Yan Hua Hospital and Yan Hua Phoenix
"Yan Hua IOT Agreement"	the hospital management right and investment framework agreement dated February 1, 2008 and the Yan Hua Hospital Investment Management Agreement, both of which were supplemented in April 2008, December 2010, June 2011, June 2013, July 2013, September 2013 and October 2013, entered into by CR Hospital Management & Consulting with Yan Hua Phoenix and Yan Hua Hospital Group

"Yanhua Parties"	Yan Hua Phoenix and Yan Hua Hospital
"Yan Hua Phoenix"	Beijing Yan Hua Phoenix Healthcare Asset Management Co., Ltd.* (北京燕化鳳凰醫療資產管理有限公司), a limited liability company incorporated under the laws of the PRC on July 18, 2005

* *Denotes English translation of the name of a Chinese entity and is provided for identification purposes only.*

By Order of the Board
China Resources Medical Holdings Company Limited
YU Hai
Chairman

PRC, August 25, 2026

As at the date of this announcement, the Board comprises Mr. YU Hai, Mr. ZHANG Chuang, Mr. WANG Yuexing and Mr. WU Xinchun as executive Directors; Mr. FANG Xin as non-executive Director; Mr. WU Ting Yuk, Anthony, Mr. FU Tingmei, Mr. ZHOU Peng and Ms. LO Wing Sze as independent non-executive Directors.